Amgen completes Abgenix acquisition
Executive Summary
Amgen has completed its $2.2 bil. acquisition of Abgenix. The deal, inked in December, gives Amgen full ownership of metastatic colorectal cancer treatment panitumumab (1"The Pink Sheet" Dec. 19, 2005, p. 24). The companies announced March 30 that they have completed submission of the rolling panitumumab BLA...
You may also be interested in...
Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA
Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.